We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+24.41%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$2.16B
AUM Growth
+$121M
Cap. Flow
-$26.6M
Cap. Flow %
-1.23%
Top 10 Hldgs %
45.97%
Holding
84
New
9
Increased
5
Reduced
5
Closed
5

Top Buys

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$53.6M
2
LEGN icon
Legend Biotech
LEGN
+$39.2M
3
AKRO
Akero Therapeutics
AKRO
+$38.7M
4
IMGN
Immunogen Inc
IMGN
+$35M
5
ARGX icon
argenx
ARGX
+$29.5M

Top Sells

Rank Stock Value
1
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$204M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$40.5M
3
BLU
BELLUS Health Inc.
BLU
+$23M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$22.6M
5
MORF
Morphic Holding, Inc. Common Stock
MORF
+$7.53M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VERU icon
76
Veru
VERU
$36M
$413K 0.02%
34,730
– –
BLCM
77
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$167K 0.01%
+450,000
New +$243K
NUVB.WS
78
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$44K ﹤0.01%
266,666
– –
SRZNW icon
79
Surrozen Inc Warrant
SRZNW
$69.7K
$4K ﹤0.01%
66,666
– –
MORF
80
DELISTED
Morphic Holding, Inc. Common Stock
MORF
– –
-200,000
Closed -$7.53M
SGEN
81
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-200,000
Closed -$40.5M
BLU
82
DELISTED
BELLUS Health Inc.
BLU
– –
-3,200,000
Closed -$23M
RXDX
83
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
– –
-1,897,500
Closed -$204M
PANA
84
DELISTED
Panacea Acquisition Corp. II Class A Ordinary Shares
PANA
– –
-500,000
Closed -$5.11M
1 2 3
4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q2 2023 Portfolio in Review

As of Q2 2023, Boxer Capital held 84 positions worth $2.16B, up 5.9% from $2.04B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Boxer Capital's Q2 2023 filing shows 9 new, 5 increased, 5 reduced and 5 closed positions. Its largest new stake was Karuna Therapeutics, Inc. Common Stock: 250,000 shares worth $54.2M. The largest sale was Prometheus Biosciences, Inc. Common Stock, an estimated $204M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

  • Boxer Capital's largest Q2 2023 buy was Karuna Therapeutics, Inc. Common Stock: 250,000 shares worth $54.2M.
  • Boxer Capital added most to Akero Therapeutics in Q2 2023, an estimated $38.7M increase.
  • Boxer Capital's biggest Q2 2023 reduction was Sarepta Therapeutics, cutting an estimated $22.6M.
  • Boxer Capital fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $204M.
  • Boxer Capital's ten largest holdings make up 46% of its $2.16B portfolio in Q2 2023.
  • Boxer Capital opened 9 new positions and closed 5 in Q2 2023.
  • Boxer Capital's portfolio value rose 5.9% quarter-over-quarter to $2.16B.

Based on Boxer Capital's 13F filing for Q2 2023, filed 14 Aug 2023.